Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 36, 2013, Pages 14598-14603

  Moore, Sarah J ^a,b,c   Hayden Gephart, Melanie G ^a,b,c   Bergen, Jamie M ^a,b,c   Su, YouRong S ^a,b   Rayburn, Helen ^a,b   Scott, Matthew P ^a,b,c   Cochran, Jennifer R ^a,b,c  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

Hedgehog pathway; Miniprotein; Protein engineering; Tumor targeting

Indexed keywords

BINDING PROTEIN; EETI 2 5F; FLUORESCENT DYE; INTERGRIN BINDING PROTEIN; KNOTTIN; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; CELL SURFACE RECEPTOR; GREEN FLUORESCENT PROTEIN; PATCHED RECEPTORS; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTRAST; CONTROLLED STUDY; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VIVO STUDY; MALE; MEDULLOBLASTOMA; MOUSE; NEUROIMAGING; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; SIGNAL DETECTION; TUMOR VOLUME; ANIMAL; CEREBELLAR NEOPLASMS; CHEMISTRY; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULAR IMAGING; NUDE MOUSE; PROCEDURES; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ERINACEIDAE; MUS;

ANIMALS; CEREBELLAR NEOPLASMS; CYSTINE-KNOT MINIPROTEINS; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; INTEGRIN ALPHA5BETA1; MALE; MEDULLOBLASTOMA; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY;

EID: 84883442008     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311333110     Document Type: Article

References (55)

1. Huse JT, Holland EC (2010) Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10(5):319-331.
2. Gibson P, et al. (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468(7327):1095-1099.
3. Pollack IF (2011) Multidisciplinary management of childhood brain tumors: A review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 8(2):135-148.
4. Saury JM, Emanuelson I (2011) Cognitive consequences of the treatment of medulloblastoma among children. Pediatr Neurol 44(1):21-30.
5. Paulino AC, et al. (2011) Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer 117(3):635-641.
6. Wu X, et al. (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482(7386):529-533.
7. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34(1):45-61. (Pubitemid 24015065)
8. Devaux BC, O' Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78(5):767-775. (Pubitemid 23121919)
9. Lacroix M, et al. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95(2):190-198. (Pubitemid 32799739)
10. Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov 9(10):804-820.
11. Gaertner FC, Schwaiger M, Beer AJ (2010) Molecular imaging of αvβ3 expression in cancer patients. Q J Nucl Med Mol Imaging 54(3):309-326.
12. Brooks PC, et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7):1157-1164.
13. DeLay M, et al. (2012) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18(10):2930-2942.
14. Friedlander M, et al. (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270(5241):1500-1502. (Pubitemid 3005294)
15. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285(5430):1028-1032.
16. Janouskova H, et al. (2012) Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res 72(14):3463-3470.
17. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156(4):1345-1362. (Pubitemid 30660012)
18. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9-22.
19. Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacol Sci 33(7):405-412.
20. Dechantsreiter MA, et al. (1999) N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42(16):3033-3040. (Pubitemid 29384038)
21. Haubner R, Beer AJ, Wang H, Chen X (2010) Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 37(Suppl 1):S86-S103.
22. Liu Z, Wang F (2010) Dual-targeted molecular probes for cancer imaging. Curr Pharm Biotechnol 11(6):610-619.
23. Kimura RH, Levin AM, Cochran FV, Cochran JR (2009) Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 77(2):359-369.
24. Kolmar H (2011) Natural and engineered cystine knot miniproteins for diagnostic and therapeutic applications. Curr Pharm Des 17(38):4329-4336.
25. Kimura RH, Cheng Z, Gambhir SS, Cochran JR (2009) Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 69(6):2435-2442.
26. Moore SJ, Leung CL, Cochran JR (2011) Knottins: Disulfide-bonded therapeutic and diagnostic peptides. Drug Discov Today Technol 9(1):e3-e11.
27. Lumpkin EA, et al. (2003) Math1-driven GFP expression in the developing nervous system of transgenic mice. Gene Expr Patterns 3(4):389-395. (Pubitemid 36950409)
28. Hahn H, et al. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85(6):841-851. (Pubitemid 26192135)
29. Johnson RL, et al. (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272(5268):1668-1671. (Pubitemid 26200029)
30. Cho YJ, et al. (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424-1430.
31. Northcott PA, et al. (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414.
32. Silverman AP, Levin AM, Lahti JL, Cochran JR (2009) Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol 385(4):1064-1075.
33. Haubner R, et al. (1996) Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alphavbeta3 antagonists. J Am Chem Soc 118(32):7461-7472. (Pubitemid 26279800)
34. Schnell O, et al. (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-oncol 11(6):861-870.
35. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8(10):2861-2871.
36. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268.
37. Orlova A, et al. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66(8):4339-4348.
38. Zahnd C, et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res 70(4):1595-1605.
39. Beer AJ, Schwaiger M (2008) Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 27(4):631-644.
40. Chen X, Conti PS, Moats RA (2004) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 64(21):8009-8014. (Pubitemid 39446936)
41. Wang W, et al. (2004) Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 3(4):343-351. (Pubitemid 40245456)
42. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X (2005) Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 16(6):1433-1441. (Pubitemid 41681509)
43. Hsu AR, et al. (2006) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 8(6):315-323. (Pubitemid 44741368)
44. Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR (2010) A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 21(3):436-444.
45. Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: The first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10(10):753-768.
46. Stroud MR, Hansen SJ, Olson JM (2011) In vivo bio-imaging using chlorotoxin-based conjugates. Curr Pharm Des 17(38):4362-4371.
47. Veiseh M, et al. (2007) Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67(14):6882-6888. (Pubitemid 47105535)
48. Stummer W, et al. (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93(6):1003-1013. (Pubitemid 32800611)
49. Constantin G (2008) Chemokine signaling and integrin activation in lymphocyte migration into the inflamed brain. J Neuroimmunol 198(1-2):20-26.
50. Milner R, Campbell IL (2002) Cytokines regulate microglial adhesion to laminin and astrocyte extracellular matrix via protein kinase C-dependent activation of the alpha6beta1 integrin. J Neurosci 22(5):1562-1572. (Pubitemid 35386275)
51. Stummer W, et al.; ALA-Glioma Study Group (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392-401.
52. Deeken JF, Löscher W (2007) The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin Cancer Res 13(6):1663-1674. (Pubitemid 46952931)
53. Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J Clin Oncol 25(16):2306-2312.
54. Lockman PR, et al. (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664-5678.
55. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37(1):48-57.